|
1.
|
Hollingsworth JM, Miller DC, Daignault S
and Hollenbeck BK: Rising incidence of small renal masses: a need
to reassess treatment effect. J Natl Cancer Inst. 98:1331–1334.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Devita VT Jr, Hellman S and Rosenberg SA:
Cancer Principles and Practice of Oncology. 8th edition. Lippincott
Williams & Wilkins; 2008
|
|
3.
|
Ljungberg B, Cowan NC, Hanbury DC, Hora M,
Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC;
European Association of Urology Guideline Group: EAU guidelines on
renal cell carcinoma: the 2010 update. Eur Urol. 58:398–406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Slaby O, Jancovicova J, Lakomy R, Svoboda
M, Poprach A, Fabian P, Kren L, Michalek J and Vyzula R: Expression
of miRNA-106b in conventional renal cell carcinoma is a potential
marker for prediction of early metastasis after nephrectomy. J Exp
Clin Cancer Res. 29:902010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M,
Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M,
Harris CC and Croce CM: A microRNA expression signature of human
solid tumors defines cancer gene targets. Proc Natl Acad Sci USA.
103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant
KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt
DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M:
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chim SS, Shing TK, Hung EC, Leung TY, Lau
TK, Chiu RW and Lo YM: Detection and characterization of placental
microRNAs in maternal plasma. Clin Chem. 54:482–490. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hunter MP, Ismail N, Zhang X, Aguda BD,
Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam
SP, Jarjoura D and Marsh CB: Detection of microRNA expression in
human peripheral blood microvesicles. PLoS One. 3:e36942008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Roth C, Rack B, Müller V, Janni W, Pantel
K and Schwarzenbach H: Circulating microRNAs as blood-based markers
for patients with primary and metastatic breast cancer. Breast
Cancer Res. 12:R902010. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nakada C, Tsukamoto Y, Matsuura K, Nguyen
TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M and Moriyama M:
Overexpression of miR-210, a downstream target of HIF1α, causes
centrosome amplification in renal carcinoma cells. J Pathol.
224:280–288. 2011.PubMed/NCBI
|
|
12.
|
Crosby ME, Kulshreshtha R, Ivan M and
Glazer PM: MicroRNA regulation of DNA repair gene expression in
hypoxic stress. Cancer Res. 69:1221–1229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Fasanaro P, D’Alessandra Y, Di Stefano V,
Melchionna R, Romani S, Pompilio G, Capogrossi MC and Martelli F:
MicroRNA-210 modulates endothelial cell response to hypoxia and
inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol
Chem. 283:15878–15883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Heneghan HM, Miller N, Lowery AJ, Sweeney
KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally
invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Tsujiura M, Ichikawa D, Komatsu S,
Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi
K, Fujiwara H, Okamoto K and Otsuji E: Circulating microRNAs in
plasma of patients with gastric cancers. Br J Cancer.
102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Mahn R, Heukamp LC, Rogenhofer S, von
Ruecker A, Müller SC and Ellinger J: Circulating microRNAs (miRNA)
in serum of patients with prostate cancer. Urology. 77:1265.e9–16.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Redova M, Svoboda M and Slaby O: MicroRNAs
and their target gene networks in renal cell carcinoma. Biochem
Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
White NM, Bao TT, Grigull J, Youssef YM,
Girgis A, Diamandis M, Fatoohi E, Metias M, Honey RJ, Stewart R,
Pace KT, Bjarnason GA and Yousef GM: miRNA profiling for clear cell
renal cell carcinoma: biomarker discovery and identification of
potential controls and consequences of miRNA dysregulation. J Urol.
186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wotschofsky Z, Busch J, Jung M,
Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller
K, Kristiansen G, Erbersdobler A and Jung K: Diagnostic and
prognostic potential of differentially expressed miRNAs between
metastatic and nonmetastatic renal cell carcinoma at the time of
nephrectomy. Clin Chim Acta. 416:5–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wulfken LM, Moritz R, Ohlmann C,
Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel
G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell
carcinoma: diagnostic implications of serum miR-1233 levels. PLoS
One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Redova M, Poprach A, Nekvindova J, Iliev
R, Radova L, Lakomy R, Svoboda M, Vyzula R and Slaby O: Circulating
miR-378 and miR-451 in serum are potential biomarkers for renal
cell carcinoma. J Transl Med. 10:552012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hauser S, Wulfken LM, Holdenrieder S,
Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E,
Walgenbach-Brünagel G, von Ruecker A, Müller SC and Ellinger J:
Analysis of serum microRNAs (miR-26a-2*, miR-191,
miR-337-3p and miR-378) as potential biomarkers in renal cell
carcinoma. Cancer Epidemiol. 36:391–394. 2012.
|
|
23.
|
Zhao A, Li G, Péoc’h M, Genin C and
Gigante M: Serum miR-210 as a novel biomarker for molecular
diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol.
94:115–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kroh EM, Parkin RK, Mitchell PS and Tewari
M: Analysis of circulating microRNA biomarkers in plasma and serum
using quantitative reverse transcription-PCR (qRT-PCR). Methods.
50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Song J, Bai Z, Han W, Zhang J, Meng H, Bi
J, Ma X, Han S and Zhang Z: Identification of suitable reference
genes for qPCR analysis of serum microRNA in gastric cancer
patients. Dig Dis Sci. 57:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Cheng Y, Wang X, Yang J, Duan X, Yao Y,
Shi X, Chen Z, Fan Z, Liu X, Qin S, Tang X and Zhang C: A
translational study of urine miRNAs in acute myocardial infarction.
J Mol Cell Cardiol. 53:668–676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Camps C, Buffa FM, Colella S, Moore J,
Sotiriou C, Sheldon H, Harris AL, Gleadle JM and Ragoussis J:
hsa-miR-210 is induced by hypoxia and is an independent prognostic
factor in breast cancer. Clin Cancer Res. 14:1340–1348. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Jung EJ, Santarpia L, Kim J, Esteva FJ,
Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai
L and Calin GA: Plasma microRNA 210 levels correlate with
sensitivity to trastuzumab and tumor presence in breast cancer
patients. Cancer. 118:2603–2614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization Classification of Tumours.
Pathology and Genetics of Tumours of the Urinary System and Male
Genital Organs. IARC Press; Lyon: pp. 9–87. 2004
|
